Skip to main content
Research project

Developing immunostimulatory antibodies to deliver agonism without toxicity

Staff

Lead researcher

Professor Aymen Al-Shamkhani

Professor in Immunology

Research interests

  • Cancer Immunotherapy
  • Immunobiology of costimulatory receptors
  • Immunostimulatory antibodies
Other researchers

Professor Jonathan Essex

Professor

Professor Mark Cragg

Professor in Experimental Cancer Biology

Research interests

  • Antibody biology
  • Antibody engineering
  • Cancer Immunotherapy

Professor Stephen Beers

Professor of Immunology & Immunotherapy

Research interests

  • Edit
  • Antibody Effector Functions Monoclonal antibodies (mAb) have become established in the treatment of a variety of malignancies - transforming patient outcomes. Despite this undoubted impact, responses remain variable and their mechanisms of action and of tumour resistance are controversial. Our research is focussed on understanding these complex processes using a variety of complementary models and systems to better inform antibody selection, design and clinical application.
  • Current research interests:

Professor Peter Johnson CBE MD FRCP FMedSci

Professor of Medical Oncology

Dr Ali Roghanian PhD, FHEA

Associate Professor

Research interests

  • Cancer immunotherapy
  • Monoclonal antibodies
  • Immunoinhibitory receptors

Dr Ivo Tews

Associate Professor

Research interests

  • Natural products biosynthesis: a complex cascade of catalytic steps in vitamin B6 biosynthesis is characterised by structures or reaction intermediates in the large PLP syntase complexEdit
  • Bacterial biofilms: understanding of RedOx regulated phosphodiesterase activity in dispersal of biofilms to address chronic infections
  • Cancer immunology: together with Cancer Immunology at Southampton we use a structure based apporach in developing novel cancer therapie

Collaborating research institutes, centres and groups

Back
to top